Mantle Cell Lymphoma | Specialty

The OncLive Mantle Cell Lymphoma condition center page is a comprehensive resource for clinical news and expert insights on mantle cell lymphoma treatment. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, therapeutic advances, and ongoing research in mantle cell lymphoma.

Dr. Ruan on Treatment Considerations in MCL

November 23rd 2020

Jia Ruan, MD, PhD, discusses treatment considerations in mantle cell lymphoma.

Dr. Skarbnik on Current Treatment Strategies Making Waves in MCL

November 19th 2020

Alan P. Z. Skarbnik, MD, discusses treatment strategies for patients with mantle cell lymphoma.

CAR T-Cell Combinations May Offer a Way to Overcome Antigen Escape in MCL

November 19th 2020

Joshua Brody, MD, discusses advances made with CAR T-cell therapy in MCL, the promise of venetoclax in B-cell malignancies, and the potential for bispecific antibody combination regimens in this disease.

Dr. Brody on the Potential Role for Bispecific Antibodies in MCL

November 18th 2020

Joshua Brody, MD, discusses the potential role for bispecific antibodies in mantle cell lymphoma.

Dr. Ruan on the Evolving Armamentarium in MCL

November 16th 2020

Jia Ruan, MD, PhD, discusses the evolving armamentarium in mantle cell lymphoma.

Dr. Brody on the Challenges of Antigen Escape in MCL

November 12th 2020

Joshua Brody, MD, discusses the challenges of mitigating antigen escape in mantle cell lymphoma.

Dr. Ruan on the Incidence of MCL

November 10th 2020

Jia Ruan, MD, PhD, discusses the incidence of mantle cell lymphoma.

Dr. Skarbnik on the Approval of Brexucabtagene Autoleucel in MCL

November 9th 2020

Alan P. Z. Skarbnik, MD, discusses the approval of brexucabtagene autoleucel in relapsed/refractory mantle cell lymphoma.

Dr. Hill on Next Steps for Research Exploring CAR T-Cell Therapy in MCL

October 26th 2020

Brian T. Hill, MD, PhD, discusses next steps for research examining CAR T-cell therapy in mantle cell lymphoma.

Dr. Jacobson on FDA Approval of Brexucabtagene Autoleucel in Relapsed/Refractory MCL

October 26th 2020

Caron Jacobson, MD, discusses the approval of brexucabtagene autoleucel in mantle cell lymphoma.

Dr. Skarbnik on Selecting Between BTK Inhibitors in MCL

October 23rd 2020

Alan P. Z. Skarbnik, MD, discusses factors to consider in selecting between BTK inhibitors in mantle cell lymphoma.

Dr. Hill on the Impact of the COVID-19 Pandemic in MCL

October 21st 2020

Brian T. Hill, MD, PhD, discusses the impact of the coronavirus disease 2019 pandemic on patients with mantle cell lymphoma.

Brexucabtagene Autoleucel  Approval in MCL Switches Up Paradigm, Brings on Sequencing Challenges

October 21st 2020

Brian T. Hill, MD, PhD, reflects on how the approval of CAR T-cell therapy has impacted clinical practice for his patients with MCL, ongoing research with practice-changing implications, and how MCL treatment has evolved during the coronavirus disease 2019 pandemic.

Dr. Hill on the FDA Approval of Brexucabtagene Autoleucel in Relapsed/Refractory MCL

October 20th 2020

Brian T. Hill, MD, PhD, discusses the FDA approval of brexucabtagene autoleucel for patients with relapsed/refractory mantle cell lymphoma.

CAR T-Cell Therapy Enters a New Era in Lymphomas, But More Lessons to Learn

October 20th 2020

Brian T. Hill, MD, PhD, discusses the advent of CAR T-cell therapies, such as axicabtagene ciloleucel, tisagenlecleucel, and brexucabtagene autoleucel, and how they have shifted lymphoma treatment into a new era.

KTE-X19 Granted Positive EU Opinion for Relapsed/Refractory MCL

October 16th 2020

The European Medicines Agency’s Committee for Medicinal Products for Human Use has adopted a positive opinion for KTE-X19 as a treatment in adult patients with relapsed/refractory mantle cell lymphoma who previously received 2 or more lines of systemic therapy, including a BTK inhibitor.

Dr. Visco on Results from the MANTLE-FIRST Study in Relapsed/Refractory MCL

October 15th 2020

Carlo Visco, MD, discusses the results of early relapse versus late relapse in the MANTLE-FIRST study with ibrutinib versus chemoimmunotherapy in mantle cell lymphoma.

Dr. Martin on the Need for Head-to-Head Comparisons of BTK Inhibitors in MCL

October 12th 2020

Peter Martin, MD, discusses the need for head-to-head comparison of BTK inhibitors in mantle cell lymphoma.

Dr. Goy on the Utility of NGS in Identifying Aggressive MCL Subtypes

October 1st 2020

Andre Goy, MD, MS, discusses the utility of next-generation sequencing in identifying aggressive subtypes of mantle cell lymphoma.

Ibrutinib Improves Outcomes in Younger Patients With Early-Relapse MCL

September 30th 2020

Carlo Visco, MD, discusses the results from the MANTLE-FIRST trial and the next steps for the research.